Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on October 24, 2007. The filing reports the entry into a material agreement regarding a public offering of common stock.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data disclosed relates to the capital raise:
- Shares Offered: 10,000,000 shares of common stock.
- Public Offering Price: $5.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,500,000 additional shares.
- Underwriter: UBS Securities LLC, as representative.
Material Changes
The material change reported is the execution of an Underwriting Agreement dated October 24, 2007, facilitating the sale of the aforementioned shares. The shares were registered under a Form S-3 Registration Statement initially filed on July 24, 2007, and a Rule 462(b) Registration Statement filed on October 24, 2007.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, future guidance, specific risk factors, or contingencies beyond the standard disclosure of the underwriting agreement and the existence of an over-allotment option.
Investor Verification Checklist
- Verify the final closing date and total proceeds from the offering, including whether the over-allotment option was exercised.
- Review the final Prospectus Supplement dated October 24, 2007, for use of proceeds and underwriting discounts.
- Confirm the post-offering share count and dilution impact on existing shareholders.
- Check subsequent filings for any changes in the company's capital structure or liquidity position resulting from this transaction.